O&G · free tool
Guideline Finder
The guidelines and RANZCOG statements your exam answers should name: what each recommends, a sentence you can write to cite it, what changed recently and the outdated answer to avoid. Quiz yourself, flip flashcards, print a cheat sheet. Free, no sign-up.
40 guidelines · 34 from RANZCOG · 9 recently changed · checked 2026-11
You know 0%
RANZCOG exam guideline cheat sheet · checked 2026-11 · fellowshipready.com.au
Postpartum haemorrhage: uterotonics, tranexamic acid and escalation: Management of Postpartum Haemorrhage (PPH) (C-Obs 43) (RANZCOG, Version 4.1 (November 2021)). Severe PPH is now defined by haemodynamic compromise as well as volume; quantify loss by weighing rather than visual estimate. Atony: oxytocin 5 units slow IV then infusion; ergometrine 0.25 mg IM/IV repeated to 1 mg if no contraindication; carboprost 0.25 mg IM at least 15 minutes apart to a maximum of 2 mg (8 doses), avoid in significant asthma; misoprostol up to 1000 micrograms PR. Tranexamic acid 1 g IV as soon as possible after onset, repeated after 30 minutes if bleeding continues. Work through the 4 Ts, replace fibrinogen if below about 1.5–2 g/L, activate the massive transfusion protocol and move to theatre early (balloon, B-Lynch, embolisation, hysterectomy).
CTG vs intermittent auscultation in labour: Intrapartum Fetal Surveillance (C-Obs 1) (RANZCOG, Version 5.2 (2026)). Offer continuous CTG when risk factors are present antenatally, at labour onset or arise in labour; for women without risk factors, intermittent auscultation is an appropriate option. Discuss the limited benefit and possible harms of an admission CTG with women without risk factors rather than performing it routinely. CTG features are interpreted descriptively against the fetus's own earlier trace, tiered from low probability of compromise to likely compromise needing urgent action. Fetal blood sampling (lactate or pH) may be used when the CTG is abnormal but birth is not immediately needed; avoid it before 34 weeks or with non-vertex presentation.
Pre-eclampsia: first-trimester screening and aspirin: Early Pregnancy Screening and Prevention of Preterm Preeclampsia and Related Complications (C-Obs 61) (RANZCOG, 2024). Offer all women first-trimester screening for preterm pre-eclampsia (11+0 to 14+1 weeks) using the FMF combined algorithm: history, mean arterial pressure, uterine artery PI and PAPP-A and/or PlGF. A risk of 1 in 100 or higher is the cut-off for offering prophylaxis (about a 10% screen-positive rate). Aspirin at least 100 mg daily (150 mg may be more effective), started before 16 weeks and stopped at 36 weeks or birth. Calcium over 1 g daily may be added for women at increased risk, but only alongside aspirin.
Anti-D: routine and event doses: Guideline for the prophylactic use of Rh D immunoglobulin in pregnancy care (National Blood Authority (with RANZCOG), 2024 (version 1.0)). Routine antenatal prophylaxis: 625 IU at 28 and 34 weeks for Rh D negative women without preformed anti-D. Sensitising events: 250 IU up to 12 weeks (e.g. ectopic, molar pregnancy, CVS); 625 IU after 12+6 weeks (e.g. APH, abdominal trauma, ECV), ideally within 72 hours and up to 10 days. Postnatal 625 IU if the baby is Rh D positive; quantify fetomaternal haemorrhage after 20 weeks and at birth (flow cytometry preferred) and give 100 IU extra per mL above 6 mL. Fetal RHD genotyping by NIPT can target prophylaxis when available; give universal prophylaxis until it is.
VBAC: counselling, induction and rupture risk: Birth After Caesarean (C-Obs 38) (RANZCOG, Version 4.1 (August 2025)). Most women with one previous caesarean can be offered planned VBAC after individual risk assessment; about 65–70% who plan it give birth vaginally. Uterine rupture occurs in roughly 1 in 122 to 1 in 500 planned VBACs and is more likely with induction and oxytocin augmentation. Not recommended after classical, inverted T or low vertical incision, previous rupture or major uterine reconstruction; review the previous operation note. Misoprostol and dinoprostone are contraindicated with a uterine scar; mechanical ripening, ARM and cautious oxytocin can be discussed; offer continuous CTG and epidural.
Breech at term: ECV and vaginal breech selection: Management of Breech Presentation at Term (C-Obs 11) (RANZCOG, July 2021). Offer ECV from 37+0 weeks (pragmatically from 36+0 in nulliparous women); success about 40% in nulliparous and 60% in multiparous women, improved by tocolysis. Give anti-D to Rh D negative women within 72 hours of ECV whether or not it succeeds. Absolute contraindications include praevia needing caesarean, APH within 7 days, abnormal CTG, ruptured membranes and multiple pregnancy. Planned vaginal breech: frank or complete breech, EFW between the 10th centile and 3.8 kg, no neck hyperextension, avoid induction, continuous CTG, and caesarean if the breech is not visible after 2 hours of passive second stage.
Instrumental birth: prerequisites, limits and antibiotics: Instrumental Vaginal Birth (C-Obs 16) (RANZCOG, March 2020). Prerequisites: fully dilated, membranes ruptured, vertex with no more than one-fifth palpable, position known, adequate analgesia, bladder empty, consent, and caesarean available within 30 minutes for mid-cavity births. Vacuum: suggested upper limit 20 minutes from first application, and generally no more than three pulls without descent; abandon if no descent with moderate traction. Forceps succeed more often but cause more anal sphincter injury; sequential instruments increase trauma. Consider a single prophylactic dose of IV amoxicillin-clavulanate 1 g/200 mg after assisted birth (ANODE trial).
Term prelabour rupture of membranes: Term Prelabour Rupture of Membranes (Term PROM) (C-Obs 36) (RANZCOG, July 2021). Confirm with sterile speculum if uncertain; avoid digital vaginal examination unless induction is about to start. Induce within 24 hours where practical: planned early birth reduces chorioamnionitis and early-onset neonatal sepsis without raising caesarean rates. GBS-positive women need intrapartum antibiotics and early induction; GBS-negative women having timely induction do not need routine antibiotics. Expectant management is an option after counselling, with 4-hourly temperature checks and attention to liquor and fetal movements.
Aneuploidy screening: NIPT, CFTS and diagnostic testing: Screening and Diagnosis of Fetal Structural Anomalies and Chromosome Conditions (C-Obs 35) (RANZCOG, Version 3.0 (2024)). Discuss NIPT (accurate for trisomies 21, 18, 13 from 10 weeks) with every woman interested in screening; CFTS is the recommended screen for those who do not access NIPT. Any high-chance screening result should be confirmed by diagnostic testing (CVS or amniocentesis) before management decisions. Offer two anomaly scans: 11–14 weeks and 18–22 weeks; the first does not replace the second. Chromosomal microarray is recommended when a structural anomaly is seen; expanded NIPT for rare autosomal trisomies and CNVs is not offered routinely.
Reproductive genetic carrier screening (CF, SMA, fragile X): Genetic Carrier Screening (C-Obs 63) (RANZCOG, Version 1.2 (December 2024; Australian interim update July 2024)). Offer carrier screening to all women and couples planning pregnancy or pregnant, regardless of family history or ethnicity; preconception is preferred. Minimum offer is cystic fibrosis, spinal muscular atrophy and fragile X; offer thalassaemia screening by FBE to all pregnant women. In Australia the three-gene panel is Medicare-funded once per lifetime; partner testing follows sequentially if the woman is a carrier of CF or SMA. People with a family history of one of these conditions should be referred to genetics rather than given the panel; high-risk couples need genetic counselling.
Monochorionic twins: surveillance, TTTS and timing of birth: Management of Monochorionic Twin Pregnancy (C-Obs 42) (RANZCOG, March 2021). Determine and document chorionicity by ultrasound before 14 weeks. Scan monochorionic twins every two weeks from 16 weeks for TTTS and growth restriction, adding umbilical artery and MCA Dopplers from 20 weeks. Refer early for laser ablation for TTTS needing treatment; selective FGR is EFW below the 10th centile with over 25% discordance; TAPS is diagnosed on MCA peak systolic velocity discordance. Plan birth by 37+0 weeks for uncomplicated monochorionic diamniotic twins.
Short cervix: cervical length screening and progesterone: Measurement of Cervical Length for Prediction of Preterm Birth (C-Obs 27) (RANZCOG, November 2021). Assess cervical length at the mid-trimester scan (around 20 weeks); proceed to transvaginal measurement if the transabdominal length is under 35 mm or not clearly seen. A transvaginal cervical length of 25 mm or less is short; vaginal progesterone (e.g. 200 mg nightly) is the preferred treatment. Consider cerclage for a cervix under 10 mm, prior preterm birth or mid-trimester loss, or shortening despite progesterone. Cervical pessaries are not supported for preventing preterm birth.
Vasa praevia: screening and timing of birth: Vasa Praevia (C-Obs 47) (RANZCOG, Version 3 (July 2025)). Offer screening to all women at the second-trimester anatomy scan, not just those with risk factors. Risk features (velamentous insertion, bilobed or succenturiate placenta, low-lying placenta, IVF, multiple pregnancy) need transvaginal colour Doppler confirmation at 28–32 weeks. Fetal vessels within 2 cm of the internal os on a transvaginal scan from 28 weeks are diagnostic; 2–5 cm is low-lying and should be rescanned. Discuss inpatient vs outpatient care from 32+0 weeks; plan caesarean from 36+0 weeks if asymptomatic without preterm risk factors, or from 34+0 weeks if risk factors are present.
Placenta accreta spectrum: diagnosis and planning: Placenta Accreta Spectrum (PAS) (C-Obs 20) (RANZCOG, March 2023). Main risk factors: previous caesarean and placenta praevia, plus older age and multiparity. Ultrasound by a clinician skilled in PAS is first-line; MRI is an adjunct when ultrasound is uncertain or the placenta is posterior. Probable or confirmed PAS should be planned by a multidisciplinary team experienced in complex pelvic surgery, including place of birth. Uterus-conserving approaches may be considered as an alternative to caesarean hysterectomy in selected, counselled women; routine prophylactic arterial balloons and methotrexate are not recommended.
Congenital CMV prevention and testing: Prevention of Congenital Cytomegalovirus (CMV) Infection (C-Obs 64) (RANZCOG, Version 1.3 (interim update 2026)). Give CMV hygiene advice to all pregnant women and those planning pregnancy, whatever their serostatus (hand washing, not sharing food or utensils with young children, no kissing on the lips). Offer CMV IgG testing before or early in pregnancy to women at higher exposure risk (parents of young children, childcare workers); it may be offered to all with counselling and clear follow-up. Do not routinely order CMV IgM or serially retest seronegative women. High-dose valaciclovir may be considered for confirmed first-trimester primary infection after specialist counselling (off-label); test the baby by saliva or urine PCR within 21 days.
Vaccination in pregnancy: pertussis, influenza, RSV: Pre-Pregnancy and Pregnancy Related Vaccinations (C-Obs 44) (RANZCOG, Version 3.1 (interim update October 2024)). Pertussis (dTpa): one dose every pregnancy, ideally 20–32 weeks in Australia (from 16 weeks in Aotearoa New Zealand). Influenza in any trimester, every pregnancy; mRNA COVID-19 vaccination is safe at any stage. RSV: a single dose of maternal RSV vaccine (Abrysvo) at 28–36 weeks to protect the infant. Live vaccines (MMR, varicella) are contraindicated in pregnancy; avoid pregnancy for 28 days after MMR; inadvertent vaccination is not a reason for termination.
Obesity in pregnancy: Management of Obesity in Pregnancy (C-Obs 49) (RANZCOG, March 2022). Record BMI at the first visit and reweigh at least each trimester; advise IOM weight gain (5–9 kg for singleton pregnancy with obesity). High-dose folic acid 5 mg (plus 150 micrograms iodine) before conception if BMI is over 30. Offer early glucose tolerance testing and repeat at 28 weeks if normal; consider aspirin and calcium based on risk factors. Weight-based thromboprophylaxis, antenatal anaesthetic review (especially BMI over 40), and offer birth before the due date (by 39 weeks) when BMI is 50 or more.
Hypothyroidism and subclinical hypothyroidism in pregnancy: Subclinical Hypothyroidism and Hypothyroidism in Pregnancy (C-Obs 46) (RANZCOG, Version 4.1 (March 2022)). Targeted (not universal) TSH and FT4 testing: personal thyroid history, type 1 diabetes or symptoms. Women already on thyroxine usually need a 30–50% dose increase early in the first trimester (about two extra doses a week); aim for TSH in the lower half of the trimester range and check at least once a trimester. Do not screen for or treat subclinical hypothyroidism, and do not screen for TPO antibodies, as trials show no benefit. All women planning, pregnant or breastfeeding should take iodine 150 micrograms daily.
Alcohol, smoking and opioids in pregnancy: Substance Use in Pregnancy Clinical Guideline (C-Obs 53) (RANZCOG, 2024). No safe level of alcohol is known; advise avoiding alcohol at all stages, including around conception. Screen every woman early for alcohol, nicotine and other substances with a validated tool, at least twice in pregnancy, with brief intervention. Continue methadone or buprenorphine in women stable on opioid agonist treatment; detoxification carries risks for mother and baby. Offer all smokers behavioural support plus long-acting NRT patches early; nicotine vapes are a conditional second-line option.
Tubal ectopic: methotrexate vs surgery: Miscarriage, Recurrent Miscarriage and Ectopic Pregnancy (C-Gyn 38) (RANZCOG, Version 1 (March 2025)). Surgery if unstable, signs of rupture, hCG above 5000 IU/L, adnexal mass over 35 mm or contraindications to other options. Stable, mass under 35 mm and no fetal heart: hCG under 1500 allows expectant, medical or surgical care; hCG 1500 to under 5000 allows methotrexate or surgery. Methotrexate: one dose if hCG under 3000 or mass under 20 mm; two doses 4–7 days apart if hCG 3000–5000 or mass 20–35 mm. Salpingectomy is preferred to salpingostomy; offer anti-D to Rh D negative women having surgery.
Recurrent miscarriage: work-up and progesterone: Miscarriage, Recurrent Miscarriage and Ectopic Pregnancy (C-Gyn 38) (RANZCOG, Version 1 (March 2025)). Recurrent miscarriage is two or more pregnancy losses up to 20 weeks, consecutive or not. Routine tests: lupus anticoagulant, anticardiolipin antibodies, TSH and TPO antibodies, and 3D ultrasound; inherited thrombophilia and NK cell testing are not routine. Antiphospholipid syndrome: low-dose aspirin plus LMWH from a positive pregnancy test to at least 34 weeks. Vaginal micronised progesterone 400 mg twice daily to 16 weeks for women with bleeding and two or more previous miscarriages; not for those with no or one previous miscarriage.
Molar pregnancy: evacuation and hCG follow-up: Management of Gestational Trophoblastic Disease (C-Gyn 31) (RANZCOG, March 2017). Suction evacuation is the preferred method whatever the uterine size; send all products for histology; avoid oxytocics until evacuation is complete. Complete mole: weekly hCG until three consecutive normal results, then monthly for six months; partial mole: weekly until three normal results, then stop. Avoid pregnancy during follow-up (combined pill is acceptable); delay IUD until hCG is normal; register with the GTD registry. Persistent disease: hCG plateau (under 10% fall over 3 weeks), rise (over 10% over 2 weeks) or still raised at 6 months needs staging and gynae-oncology referral.
Early medical and surgical abortion: Clinical Guideline for Abortion Care (RANZCOG, Version 1.4 (2026)). Early medical abortion: mifepristone 200 mg orally then misoprostol 800 micrograms buccal, sublingual or vaginal 24–48 hours later; in Australia up to 63 days (9 weeks) under the TGA approval. Ultrasound is not routinely required if gestation can be established clinically; scan if dates are uncertain or ectopic is suspected. Telehealth delivery is safe. Rh D testing is not required before abortion up to 10 weeks; anti-D for Rh D negative women from 10 weeks. Misoprostol 400 micrograms priming 1–3 hours before surgical abortion; antibiotic prophylaxis for surgical but not medical abortion; offer immediate LARC.
Contraception: LARC, quick start and postpartum IUC: Contraception Clinical Guideline (C-Gyn 3) (RANZCOG, July 2024 (signposting guideline adapted from FSRH)). Inform women of the superior effectiveness of LARC; use the UK Medical Eligibility Criteria to judge suitability (categories 3 and 4 generally not used). Quick start is acceptable when pregnancy is reasonably excluded: extra precautions for 7 days with combined methods, 2 days with traditional or desogestrel POPs. Postpartum IUC is safe within 48 hours of birth or from 4 weeks; avoid insertion between 48 hours and 4 weeks. IUC suits young and nulliparous people; the copper IUD can also be used for emergency contraception.
Menopause: MHT and non-hormonal options: Management of Vasomotor and Genitourinary Symptoms of Menopause (C-Gyn 9) (RANZCOG, Version 12 (July 2026)). MHT is strongly recommended for troublesome vasomotor symptoms without contraindications; women with a uterus need a progestogen; review annually. Non-hormonal: neurokinin 3 receptor antagonists (e.g. fezolinetant, with LFT monitoring) and oxybutynin are strongly recommended; SSRIs/SNRIs and gabapentin conditionally; CBT, clonidine and acupuncture are not recommended. MHT is not recommended for vasomotor symptoms after breast cancer; avoid paroxetine and fluoxetine with tamoxifen. Vaginal estrogen is first-line for genitourinary symptoms, including after breast cancer (case by case with aromatase inhibitors); CO2 laser is not recommended.
Intermenstrual and postcoital bleeding: Investigation of Intermenstrual and Postcoital Bleeding (C-Gyn 6) (RANZCOG, Version 11.1 (July 2021)). Persistent intermenstrual bleeding: cervical co-test (HPV and LBC) in Australia, STI testing if at risk, transvaginal ultrasound and gynaecology referral. Postcoital bleeding: tests to exclude cervical cancer and chlamydia. A single episode of postcoital bleeding with a normal screening test and normal-looking cervix does not need immediate referral. Recurrent or persistent postcoital bleeding warrants gynaecology referral.
Endometriosis: imaging diagnosis and first-line treatment: Australian Living Evidence Guideline: Endometriosis (RANZCOG, Living guideline (2025)). Transvaginal ultrasound is the first-line investigation; MRI if ultrasound is inconclusive or deep disease is suspected. A normal scan or examination does not exclude endometriosis. Start empirical hormonal treatment without surgical confirmation: combined hormonal contraception or progestogens (LNG-IUD, implant, MPA, dienogest), with a short NSAID trial. Change agent or refer if no improvement after 3–6 months; laparoscopy may be considered even with normal imaging, ideally after a treatment trial; excise rather than ablate endometriomas. Hormonal treatment does not improve unassisted conception, so it is not used in women trying to conceive.
Heavy menstrual bleeding: LNG-IUD and alternatives to hysterectomy: Heavy Menstrual Bleeding Clinical Care Standard (ACSQHC, 2024). Assess impact on quality of life and exclude pregnancy, iron deficiency and anaemia; offer oral medical treatment (tranexamic acid, NSAIDs, hormonal) at first presentation. If imaging is needed, a quality pelvic ultrasound, preferably transvaginal, ideally on days 5–10 of the cycle. Offer the 52 mg levonorgestrel IUD when appropriate as the most effective medical option. Offer uterus-preserving options (ablation, embolisation, removal of polyps or fibroids) before hysterectomy, which is considered only when others fail or are unsuitable, or at the woman's request.
PCOS: diagnosis, screening and ovulation induction: International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023 (International PCOS Network (Monash University, NHMRC-approved), 2023). Adults: two of three features (hyperandrogenism, ovulatory dysfunction, polycystic ovaries on ultrasound or raised AMH); with irregular cycles plus hyperandrogenism, neither scan nor AMH is needed. Adolescents need both hyperandrogenism and ovulatory dysfunction; do not use ultrasound or AMH within 8 years of menarche. Screen for depression and anxiety, assess glycaemic status at diagnosis (75 g OGTT most accurate) and cardiovascular risk. COCP is first-line for irregular cycles and hyperandrogenism; letrozole is first-line pharmacological ovulation induction, with clomiphene second-line.
Stress urinary incontinence: midurethral slings: Position Statement on Midurethral Slings (C-Gyn 32) (RANZCOG, July 2020, amended March 2022). Offer supervised pelvic floor muscle training first; surgery if conservative treatment fails. Retropubic slings are generally preferred in Australia; transobturator only in exceptional cases after multidisciplinary or peer review; single-incision slings only within trials or strict governance. Consent must state the tape is polypropylene mesh and cover pain, dyspareunia, voiding dysfunction and exposure, and discuss alternatives such as Burch colposuspension and pubovaginal slings. Only surgeons who regularly do MUS should operate; record outcomes in a registry and report adverse events to the TGA.
Informed consent in O&G: Consent and Provision of Information to Patients Regarding Proposed Treatment (C-Gen 2) (RANZCOG, Version 11 (June 2026)). Valid consent is an informed choice made freely, after information on benefits, immediate and long-term risks, costs and alternatives that the patient understands. The patient may refuse or withdraw consent at any time. If the patient lacks capacity, consent comes from her substitute decision-maker, taking account of any advance care directive. The clinician is responsible for making sure consent is obtained and documented; the statement signposts the Australian Charter of Healthcare Rights, Good medical practice and ACSQHC informed consent guidance (and the HDC Code in Aotearoa New Zealand).
Female genital mutilation/cutting: Female Genital Mutilation/Cutting (FGM/C) (C-Gyn 1) (RANZCOG, Version 11.1 (September 2024)). Use the WHO four-type classification (type III is infibulation). FGM/C is illegal in every Australian state and territory and in Aotearoa New Zealand, including taking a girl overseas for it. Reinfibulation after birth must not be performed, even on request. Deinfibulation for type III may be offered antenatally or in labour; in Australia, a child at risk of or affected by FGM/C must be reported to child protection.
Timing of planned caesarean at term: Timing of Planned Caesarean Section at Term (C-Obs 23) (RANZCOG, Version 4.1 (November 2022)). Plan caesarean at 39 weeks or later for women without additional risks. Birth by planned caesarean at 37+0 to 38+6 weeks roughly doubles the odds of serious neonatal respiratory morbidity compared with 39 weeks or later. If birth before 39 weeks cannot be safely deferred, corticosteroids could be considered, noting limited evidence. Document the reason for any planned caesarean before 39 weeks.
Cervical screening: HPV results and self-collection: National Cervical Screening Clinical Guidelines (National Cervical Screening Program) (Cancer Council Australia, Living guideline (summary of recommendations updated July 2022)). Five-yearly HPV testing for people with a cervix aged 25–74 who have ever been sexually active. Everyone eligible can choose self-collected or clinician-collected samples. HPV 16/18 detected: refer directly for colposcopy (LBC guides management); other oncogenic types with negative or low-grade LBC: repeat HPV in 12 months. Exit at 70–74 with a negative HPV test; abnormal bleeding needs gynaecological assessment rather than screening.
Third and fourth degree perineal tears: Third and Fourth Degree Perineal Tears Clinical Care Standard (ACSQHC, 2021). Discuss risk antenatally; risk-reduction options include antenatal perineal massage from 34 weeks, warm compresses, controlled birth of the head and hands-on perineal support. Consider mediolateral episiotomy at instrumental birth, particularly a first vaginal birth. After every vaginal birth offer a systematic examination including rectal examination where indicated; grade with the RCOG classification. Repair promptly by a trained clinician, usually in theatre; give analgesia and laxatives, decide antibiotics case by case, and arrange pelvic floor physiotherapy and follow-up.
Perinatal depression and anxiety screening: Guidelines for preventive activities in general practice (Red Book): Perinatal depression (RACGP, 10th edition). Use the Edinburgh Postnatal Depression Scale (EPDS) to screen for perinatal depression (strong recommendation). Assess psychosocial risk with the Antenatal Risk Questionnaire (ANRQ) as early as practical in pregnancy and again after birth. Complete the first postnatal EPDS at 6–12 weeks after birth and repeat at least once in the first postnatal year. Aligned with the COPE 2023 Australian clinical practice guideline, Mental health care in the perinatal period.
Routine antenatal care and booking bloods: Routine Antenatal Assessment in the Absence of Pregnancy Complications (C-Obs 3b) (RANZCOG, Version 12.1 (March 2022)). First visit by 10 weeks: FBE, blood group and antibodies, rubella, syphilis, HIV, hepatitis B, hepatitis C (risk or local policy), MSU for asymptomatic bacteriuria; about ten visits for an uncomplicated first pregnancy. Do not test vitamin D, CMV, toxoplasma or TSH routinely. Measure fundal height at each visit and plot on a customised chart; side sleeping from 28 weeks; repeat FBE and antibody screen (Rh negative) at 28 weeks. From 41 weeks consider monitoring and advise on fetal movements; offer induction at 42 weeks or later.
Antibiotic prophylaxis at caesarean and gynae procedures: Prophylactic Antibiotics in Obstetrics and Gynaecology (C-Gen 17) (RANZCOG, March 2021). Give prophylaxis for every caesarean before skin incision (ideally about 30 minutes before): cefazolin 2 g IV, 3 g if over 120 kg, redosed after 3 hours. Severe penicillin allergy: clindamycin 600 mg IV plus gentamicin 2 mg/kg IV. No routine prophylaxis for IUD insertion, diagnostic laparoscopy, hysteroscopic surgery or LLETZ in low-risk women. After assisted vaginal birth, a single IV dose of amoxicillin-clavulanate reduces infection; prophylaxis for OASIS is decided case by case.
Normal labour: active first stage, examinations and second stage: Care in Labour in the Absence of Pregnancy Complications (C-Obs 31) (RANZCOG, 2023 (interim update March 2024)). Active first stage starts at 5 cm; it usually lasts no more than 18 hours in a first labour and 12 hours in later labours. Plan vaginal examinations no more often than 4-hourly unless there is concern or the woman asks. Escalate after 2 hours of pushing (nulliparous) or 1 hour (parous); an extra hour may be reasonable if mother and baby are well; avoid routine amniotomy. Offer delayed cord clamping (at least 60 seconds) and recommend a prophylactic uterotonic in the third stage.
Suspected fetal macrosomia: induction and caesarean thresholds: Diagnosis and Management of Suspected Fetal Macrosomia (C-Obs 65) (RANZCOG, v1.1 (November 2021)). Suspected macrosomia: ultrasound EFW and/or AC at or above the 95th centile; prediction is imprecise and best at ruling it out. Induction before 39+0 weeks may reduce shoulder dystocia and fractures but must be weighed against early-term birth; induction after 39 weeks for macrosomia alone is not routinely recommended. Consider elective caesarean for EFW of 5000 g or more without diabetes, or 4500 g or more with diabetes. Suspected macrosomia alone is not an absolute contraindication to VBAC; caesarean does not remove the brachial plexus risk entirely.
Summaries are written in our own words from each guideline's official page and are for exam study, not clinical use. Guidelines change: check the source before you rely on it.
Try 20 free questions.
RANZCOG-style questions, marked with a reason for every option. Free account, no card.
Also free: Anatomy Scroller · RANZCOG exam guides